Zacks: Analysts Expect Neon Therapeutics Inc (NTGN) Will Post Earnings of -$0.79 Per Share

Equities research analysts expect Neon Therapeutics Inc (NASDAQ:NTGN) to announce earnings of ($0.79) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Neon Therapeutics’ earnings. The lowest EPS estimate is ($0.85) and the highest is ($0.75). The business is expected to issue its next quarterly earnings results on Monday, November 12th.

On average, analysts expect that Neon Therapeutics will report full-year earnings of ($5.50) per share for the current year, with EPS estimates ranging from ($5.61) to ($5.39). For the next year, analysts expect that the company will post earnings of ($3.07) per share, with EPS estimates ranging from ($3.45) to ($2.70). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Neon Therapeutics.

A number of research firms have commented on NTGN. Morgan Stanley began coverage on shares of Neon Therapeutics in a research note on Monday, July 23rd. They set an “overweight” rating and a $23.00 price objective for the company. LADENBURG THALM/SH SH began coverage on shares of Neon Therapeutics in a research note on Monday, October 1st. They set a “buy” rating and a $20.00 price objective for the company. Oppenheimer began coverage on shares of Neon Therapeutics in a research note on Monday, July 23rd. They set a “$11.74” rating and a $20.00 price objective for the company. Bank of America began coverage on shares of Neon Therapeutics in a research note on Monday, July 23rd. They set a “buy” rating and a $18.00 price objective for the company. Finally, Cann began coverage on shares of Neon Therapeutics in a research note on Monday, July 23rd. They set an “outperform” rating and a $20.00 price objective for the company. Four research analysts have rated the stock with a buy rating, Neon Therapeutics currently has a consensus rating of “Buy” and an average target price of $20.20.

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Hong Kong Ltd acquired a new position in shares of Neon Therapeutics in the 2nd quarter valued at about $105,000. Highland Capital Management LP acquired a new position in shares of Neon Therapeutics in the 2nd quarter valued at about $137,000. Northern Trust Corp acquired a new position in shares of Neon Therapeutics in the 2nd quarter valued at about $137,000. Bank of New York Mellon Corp acquired a new position in shares of Neon Therapeutics in the 3rd quarter valued at about $141,000. Finally, Bain Capital Public Equity Management LLC acquired a new position in shares of Neon Therapeutics in the 2nd quarter valued at about $147,000. Institutional investors own 65.76% of the company’s stock.

NASDAQ NTGN traded down $0.71 on Friday, reaching $7.12. The company’s stock had a trading volume of 105,001 shares, compared to its average volume of 159,853. Neon Therapeutics has a twelve month low of $5.62 and a twelve month high of $16.23.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

See Also: What is the Dividend Aristocrat Index?

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply